Pierre Legault - Jan 12, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Jan 12, 2023
Transactions value $
-$615,802
Form type
4
Date filed
1/13/2023, 03:44 PM
Previous filing
Jan 5, 2023
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $227K +24K +75% $9.47 56K Jan 12, 2023 Direct
transaction SNDX Common Stock Sale -$642K -24K -42.86% $26.74 32K Jan 12, 2023 Direct F1, F2
transaction SNDX Common Stock Options Exercise $136K +10K +31.25% $13.58 42K Jan 13, 2023 Direct
transaction SNDX Common Stock Sale -$270K -10K -23.81% $27.00 32K Jan 13, 2023 Direct F1
transaction SNDX Common Stock Options Exercise $67.9K +5K +15.63% $13.58 37K Jan 13, 2023 Direct
transaction SNDX Common Stock Sale -$135K -5K -13.51% $27.00 32K Jan 13, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24K -100% $0.00* 0 Jan 12, 2023 Common Stock 24K $9.47 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -10K -100% $0.00* 0 Jan 13, 2023 Common Stock 10K $13.58 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -5K -100% $0.00* 0 Jan 13, 2023 Common Stock 5K $13.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $26.50 to $26.93.
F3 This option is fully vested.